ArticleEBioMedicine2017
C-Reactive Protein Mediating Immunopathological Lesions: A Potential Treatment Option for Severe Influenza A Diseases.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- C-reactive protein as a biomarker of severe H1N1 influenza.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Pooled it
- Metabolic reprogramming induced by CRP deficiency or human CRP transgenic in influenza-infected mice.Frontiers in immunology · 2026Article
- Potential of biomarkers of ageing in predicting severity of influenza virus infection and vaccination efficacy.npj aging · 2025Review
- Association of mTOR Pathway and Conformational Alterations in C-Reactive Protein in Neurodegenerative Diseases and Infections.Cellular and molecular neurobiology · 2023Review
- Epstein-Barr Virus Infection Is Associated with Elevated Hepcidin Levels.International journal of molecular sciences · 2023Article
- C-reactive protein: a target for therapy to reduce inflammation.Frontiers in immunology · 2023Review
- Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion.International journal of molecular sciences · 2022Article
- Deficiency of C-reactive protein or human C-reactive protein transgenic treatment aggravates influenza A infection in mice.Frontiers in immunology · 2022Article
- C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?European heart journal · 2021Article
- Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China.World journal of clinical cases · 2021Article
- Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2021Review
- Update Advances on C-Reactive Protein in COVID-19 and Other Viral Infections.Frontiers in immunology · 2021Review
- Fulminant Giant Cell Myocarditis vs. Lymphocytic Myocarditis: A Comparison of Their Clinical Characteristics, Treatments, and Outcomes.Frontiers in cardiovascular medicine · 2021Article
- Nomogram for the Individualized Prediction of Survival Among Patients with H7N9 Infection.Risk management and healthcare policy · 2020Article
- Selection of an Optimal Combination Panel to Better Triage COVID-19 Hospitalized Patients.Journal of inflammation research · 2020Article
- Acute phase protein response to viral infection and vaccination.Archives of biochemistry and biophysics · 2019Review
- Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome.Mucosal immunology · 2019Article
- Respiratory tract virus infections in the elderly with pneumonia.BMC geriatrics · 2019Article
- Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study.Therapeutics and clinical risk management · 2019Article
- The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe influenza diseases with high mortality have been frequently reported, especially in those patients infected with avian influenza A (H5N1, H7N9 or H10N8) or during a pandemic. Respiratory distress, which is attributed to alveolar damage associated with immunopathological lesions, is the most common cause of death. There is a wealth of information on pathogenesis or treatment options. In this study, we showed that high levels of C-reactive protein (CRP) were induced and correlated with complement activation in patients infected with severe influenza A (H5N1, H7N9 or H10N8), and higher levels were induced in fatal patients than in survivors. CRP treatment enhanced the phagocytosis of monocytes THP-1 to H5N1 virus as well as the expression of proinflammatory cytokines or apoptosis-associated genes in THP-1 cells or pneumocytes A-549 respectively. CRP may link to proinflammatory mediators contributing to activation of complement and boosting inflammatory response in severe influenza infections. Compound 1,6-bis(phosphocholine)-hexane improved the severity and mortality of mice infected with lethal influenza virus significantly. These observations showed that CRP is involved in deterioration of severe influenza diseases, and indicated a substantial candidate molecule for immunotherapy of severe influenza diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.